Metrion combines robust high-throughput KV7 assay capability with deep expertise in voltage gated potassium ion channels to help biotech and pharma teams advance programmes in pain and epilepsy with confidence.
Metrion delivers scalable KV7 IV profiling with the data quality and scientific support needed to advance ion channel programmes efficiently.
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.